



Information Security Policy Statement

At Oxford Gene Technology (OGT), protecting the confidentiality, integrity, and availability of information is fundamental to our mission of delivering high-quality genomic products and services to the global clinical and research communities.

We are committed to maintaining an effective Information Security Management System (ISMS) aligned with the principles of ISO/IEC 27001. Our ISMS underpins our operations and ensures that we safeguard sensitive information (including customer data, intellectual property, and regulatory information) against all forms of threats, whether internal or external, deliberate or accidental.

Our information security commitments are to:

- Protect all forms of information assets from loss, theft, unauthorised access, disclosure, alteration, and destruction.
- Comply with all applicable legal, regulatory, and contractual obligations, including GDPR and relevant medical device regulations.
- Embed information security responsibilities and awareness across all employees, contractors, and third-party partners.
- Continuously assess and manage risks to our information assets through systematic risk management practices.
- Respond promptly and effectively to security incidents to minimise impact and support recovery.
- Foster a culture of continual improvement through regular reviews, audits, and updates to our ISMS.
- Ensure information security objectives are set, monitored, and reviewed regularly in line with our business strategy and evolving threat landscape.

OGT's leadership team provides full support to the ISMS and ensures that sufficient resources are allocated for its effective operation. All employees and relevant external parties are expected to be aware of, and adhere to, this policy.

By adopting and enforcing these principles, OGT aims to build and maintain the trust of our customers, partners, and the wider community we serve.

This Information Security Policy Statement is publicly available and will be reviewed at least annually to ensure its ongoing relevance and effectiveness.

Date issued: 1st May 2025

Approved by: Chief Executive Officer, Oxford Gene Technology.